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Effect of Renal Ischemia on Plasma Levels of FK 506 in Rats 
M. Sakr, G. Zetti, J. Gavaler, H. Farghali, R. Venkataramanan, G. Carrieri, T. Starzl, and D. Van Thiel 
I T IS generally recognized that at steady-state conditions less than 10% of cyclosporine (CyA)1.2 or FK 5063 is 
excreted by the kidney and that renal function has little or 
no effect on the blood or plasma levels of either of these 
two drugs. Experimental studies, however, have shown 
that animals with severely impaired renal function have 
higher blood CyA trough levels than do controls.4 .5 There-
fore the presence of renal ischemia and/or nephrotoxicity 
may have an effect as yet unidentified on the regulation of 
the CyA or FK 506 blood level. 
To investigate this question, the effect of renal ischemia 
on single and multiple IV administration of FK 506 was 
studied in rats subjected to unilateral left nephrectomy and 
contralateral total renal ischemia. 
MATERIALS AND METHODS 
Experimental Protocol 
These experiments were carried out in male Lewis rats weighing 
200 to 250 g. All of the animals had been acclimatized to the 
Animal Research Laboratory for at least I week before being 
utilized for these studies. The animals were anesthetized with 
metofane administered by inhalation and when fully anesthetized. 
they were subjected to laparotomy and renal manipulation as 
described below. The animals were divided into five groups as 
follows. 
Experiment 1 (Single Dose Administration). Group I (n = 10): 
a left nephrectomy was performed and a single dose of FK 506 (0.3 
mg/kg in 0.5 mL saline) was injected IV via the inferior vena cava 
(lVC). 
Group 2 (n = 10): the right perirenal fascia was dissected. The 
right renal vessels were identified and clamped for a 60-minute 
period using nontraumatizing microvascular clamps. Upon reper-
fusion of the right kidney. a left nephrectomy was peliormed and 
a similar dose of FK 506 was injected IV via the IVe. 
From each animal in groups I and 2, blood samples (0.5 mL) 
were withdrawn from the jugular vein at 10, 20, 30, 60, 120, and 
240 minutes after saline or FK 506 administration for determina-
tion of the plasma FK 506 levels. The blood withdrawn from each 
rat at each time point was replaced with an equal volume of 
heparinized Ringers lactate. 
txperiment 2 (Multiple FK 506 Administration). Group 3 (n = 
20): animals in this group were subjected to a left nephrectomy 
and a daily IV administration ofFK 506 (0.3 mg/kg) via the jugular 
vein for a period of 10 days. 
Group 4 (n = 20): animals in this group were subjected to a left 
nephrectomy, right renal ischemia for a 60-minute period, and a 
daily IV administration of FK 506 (0.3 mg/kg) for 10 days. 
Group 5 (n = 10): animals in this group were subjected to a left 
nephrectomy and right renal ischemia for a period of 60 minutes 
without FK 506 administration. 
All animals were allowed to recover spontaneously and post-
operatively were observed regularly at 12-hour intervals for a total 
of 10 days. From each animal, blood samples were collected (from 
the jugular vein) at days 0 (preoperative), I, 2, 3, 5, 7, and 10 
(postoperatively) for blood urea nitrogen (BUN), creatinine, ala-
nine transaminase (AL T), and FK 506 levels. The blood with-
drawn from each rat was replaced with an equal volume of 
lactated Ringers solution. 
Biochemical Analyses and FK 506 Bioassay 
Serum levels of BUN, creatinine, and ALT were estimated using 
standard biochemical methods and diagnostic kits obtained from 
Sigma. FK 506 plasma concentrations were measured by a 
monoclonal antibody (MAb)-based enzyme-linked immunosor-
bent assay (ELISA) (Fujisawa Pharmaceuticals Co Ltd, Osaka, 
Japan) as described elsewhere. 6 
Statistical Analyses 
Data are reported as the mean and the standard error ofthe mean. 
BUI'< and creatinine data were analyzed using the two-way 
analysis of variance. Comparisons between the means were 
performed using the Student's t test. The chi-square test was used 
to compare the proportions of surviving animals between groups. 
A P value of < .05 was considered to be significant. 
RESULTS 
Experiment 1 
Plasma levels after a single IV dose administration of FK 
506 were fit by a monoexponential curve assuming that FK 
506 was distributed in a single compartment (Fig I). The 
rate constant of FK 506 elimination from blood was 0.004 
minute -I and 0.0038 minute -I for the data obtained from 
the nonischemic (group I) and renal ischemic (group 2) 
rats, respectively. Consequently, there was no difference 
between the FK 506 half-lives in the nonischemic and 
ischemic animals. The corresponding half-life times were 
173.3 minutes and 182.4 minutes, respectively. 
Experiment 2 
Plasma FK 506 Levels. As may be seen in Fig 2, after 
repeated daily administration of FK 506 for 10 days, the 
steady-state levels of FK 506 found in the renal ischemic 
rats (group 4) were significantly greater than those seen in 
the renal nonischemic animals (group 3) (P < .02). On days 
I and 2 after operation, the plasma FK 506 levels were 
similar in both groups. However, the FK 506 levels in-
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Fig 1. Monoexponential curve for plasma levels of FK 506 after 
a single IV dose administration in group 1 (renal non ischemic) and 
group 2 (renal ischemic) animals. 
creased rapidly on days 3 and 5 in the renal ischemic 
animals as compared with the renal nonischemic animals. 
Animal Mortality and Morbidity. All animals in groups 
3 (FK 506 alone) and 5 (ischemia alone) survived through-
out the totallO-day period of the experiment. The survival 
of group 4 animals (FK 506 + ischemia) was reduced to 
65% at 5 days postoperatively and was maintained there-
after through 10 days (P < .02) (Fig 3). 
Rats subjected to both renal ischemia and repeated 
administration of FK 506 (group 4) appeared somewhat 
emaciated with a moderate degree of hair loss as compared 
with rats subjected to either alone. A postoperative mean 
weight loss of 25.3 ± 2% and severe diarrhea (five rats) 
were noted also in the group 4 animals. The animals that 
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Fig 2. Steady state levels of FK 506 found in group 3 (renal 
nonischemic) and group 4 (renal ischemic) after repeated daily 
administration of FK 506 (*P < .02). 
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Fig 3. Survival time course of studied animals in group 3 (FK 506 
alone), group 4 (FK 506 + ischemia), and group 5 (ischemia 
alone) (* P < .02). 
died were not autopsied. Their deaths were attributed to 
renal failure as a result of ischemia, FK 506 renal toxicity, 
or both, which were amplified by hypovolemia occurring 
as a result of the diarrhea and lack of oral intake they 
experienced. 
Hepatic Injlll}' and Renal Function. Liver injury as 
assessed by the serum AL T level remained normal in all 
groups studied throughout the duration of the study. As 
shown in Figures 4 and 5, renal function remained stable in 
the group 3 animals that received FK 506 daily for 10 days. 
Animals in groups 4 (FK 506 + ischemia) and those in 
group 5 (ischemia alone) had similar abnormal serum BUN 
and creatinine levels. Both groups showed a marked 
deterioration of renal function with a maximum elevation 
of BUN and creatinine levels on day 3 after operation (P < 
.02). From this point on renal function improved daily until 
day 10 when the mean BUN and creatinine levels were not 
significantly different from those seen in the group 3 renal 
nonischemic animals. 
DISCUSSION 
FK 506 is a potent immunosuppressive agent with a high 
efficacy and a low incidence of side effects.7- 9 Similar to 
Cy A, FK 506 is almost completely metabolized in the liver 
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Fig 4. Mean serum levels of BUN (mg/dL) in group 3 (FK 506 
alone), group 4 (FK 506 + ischemia), and group 5 (ischemia 
alone) animals (* P < .02). 
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Fig 5. Mean creatinine levels (mg/dL) in group 3 (FK 506 alone), 
group 4 (FK 506 + ischemia), and group 5 (ischemia alone) 
animals (*P < .02). 
before elimination from the body and only a small percent-
age of the drug is excreted in the urine. This finding 
suggested that, in clinical transplantation, changes in FK 
506 dosing regimen may not be necessary in patients with 
renal failure or in patients on dialysis, but may be neces-
sary in patients with hepatic dysfunction. 
In clinical transplantation, it is difficult to establish 
whether renal dysfunction plays a role in determining Cy A 
or FK 506 blood levels. It has been reported that the 
elimination of parent Cy A in the urine is not markedly 
different between patients with advanced renal failure and 
bone marrow recipients with normal renal function. lo In 
contrast, experimental studies have shown that animals 
with deteriorating renal function had significantly higher 
CyA levels than animals with improving renal function. 4 .' 
To date there is little if any studies on the renal handling 
of FK 506 when function is impaired. In the present study. 
our results demonstrated that there was no dill'erence in 
the rate constant of FK 506 elimination between ischemic 
and nonischemic rats after a single IV dose of the drug (Fig 
I). However, with repeated FK 506 administration over 10 
days, renal ischemia resulted in an increase in plasma FK 
506 levels as compared with those seen in nonischemic 
animals (Fig 2). The high plasma levels of FK 506 declined 
from day 5 to day 10 after operation as renal function 
markedly improved. This indicates that the plasma level of 
FK 506 is altered by the injury associated with ischemia 
and reperf'usion and that renal impairment was responsible 
for changes in FK 506 distribution kinetics. The possibility 
of involvement of the liver in the elevation of plasma FK 
506 levels may be ruled out by the normal ALT level herein 
observed throughout the expeliment. 
Experimental data have shown that the nephrotoxic 
effect of Cy A is more pronounced in the presence of a 
renal ischemic insult. and that these two factors may act 
synergistically to produce a more severe renal functional 
impairment than is caused by either alone. I 1-14 Our results 
showed that the daily IV administration of FK 506 at a 
dose of 0.3 mg/kg for a period of 10 days causes no 
impairment of renal function. Whereas a 60-minute period 
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of ischemia resulted in deterioration of renal function, the 
concomitant daily administration of FK 506 did not aggra-
vate the renal function impairment (Fig 4 and 5) despite the 
elevated plasma FK 506 levels seen in such cases. How-
ever, it is noteworthy that in clinical transplantation. 
although some reports of Cy A nephrotoxicity have dis-
closed a close association between drug level and serum 
creatinine,15 with FK 506 a poor correlation exists be-
tween drug level and serum creatinine.9 It must be noted, 
however, that current FK 506 assays use a MAb that is not 
specific for FK 506 alone but also measures metabolites. 
While CyA-induced acute renal failure has been described, 
usually associated with toxic drug levels, this phenomenon 
was not noted with FK 506. It is therefore unlikely that 
changes in serum creatinine or BUN levels will be a 
reliable marker of FK 506 toxicity.9 
Previous studies have shown that rats can tolerate well 
a repeated administration of FK 506 at a dose of I mg/kg/d 
with no impairment in renal or liver functions. 16 In con-
trast. the present study shows that the repeated adminis-
tration of FK 506 at a dose of 0.3 mg/kg/d in the presence 
of a renal ischemic injury resulted in animal morbidity and 
even mortality (Fig 3), which were not observed with 
either alone. The profound weight loss herein observed 
suggests that FK 506 (in high levels) may result in dimin-
ished appetite and/or augmented catabolism, which may 
contribute to the raised urea levels. Severe malnutrition 
and diarrhea were clearly major factors leading to the 
deaths seen in this group since the high levels of BUN and 
creatinine seen with renal ischemia alone were not associ-
ated with any decrease in survival. No overt evidence of a 
change in behavior was noted between FK 506 and control 
treated animals. 
From the data presented it may be concluded that rats 
tolerate a daily IV dose of FK 506 (0.3 mg/kg) without 
impairment of renal function, animal morbidity or mortal-
ity. A 60-minute period of total renal ischemia results in 
reversible elevations of serum BUN and creatinine levels 
but no mortality. Renal ischemic injury results in increase 
of plasma FK 506 levels. but within the limits of this study 
the high levels of FK 506 do not further aggravate the renal 
function impairment caused by ischemia. 
Based on these data it is possible to speculate that in 
clinical transplantation, although the kidney normally 
plays a relatively minor role in the clearance ofFK 506, its 
importance in the presence of severe renal impairment 
should not be ignored. Consequently, FK 506 blood levels 
should be monitored in patients with severe renal dysfunc-
tion because even transiently high levels may increase the 
risk of drug toxicity. especially in the immediate postop-
erative period when the kidney may have experienced an 
ischemic insult. Additionally, with the return of renal 
function it is possible that plasma FK 506 concentrations 
may fall to levels that are inadequate for effective immu-
nosuppression. 
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